Glucokinase activators as new type 2 diabetes therapeutic agents

Bibliography

• Sarabu R, Taub R, Grimsby J. Glucokinase activation – a strategy for T2D therapy: Recent developments. Drug Discov Today Ther Strateg 2007;4:111-5
   Google Scholar
• Coghlan M, Leighton B. Glucokinase activators in diabetes management. Expert Opin Investig Drugs 2008;17:145-67
   PubMed Web of Science ®Google Scholar
• Matschinsky F, Magnuson MA, editors. Glucokinase and glycemic disease. S. Karger AG, Basel; 2004
   Google Scholar
• F. Hoffmann-La Roche AG. Trans olefinic glucokinase activators. WO2001044216; 2001; US6353111; 2002
   Google Scholar
• Eli Lilly and Co. Preparation of heteroaryl compounds for the treatment of type II diabetes. WO2004063194; 2004
   Google Scholar
• OSI Pharmaceuticals, Inc., USA; Prosidion Ltd; OSI Pharm Inc. Preparation of tri(cyclo) substituted amides, in particular N-(thiazol-2-yl) amides, as Glucokinase (GK) activators for treating hyperglycemia and diabetes. WO2004072031; 2004
   Google Scholar
• Tanabe Seiyaku Co., Ltd., Japan. Oxime derivatives as glucokinase activating agents and their preparations, pharmaceutical compOSItions and use in the treatment of diabetes and related diseases. WO2007007886; 2007
   Google Scholar
• Novartis A-G, Switz. Preparation of N-2-thiazolylsulfonamides and related compounds as glycokinase activators for the treatment of type 2 diabetes. WO2004050645; 2004
   Google Scholar
• Eli Lilly and Company, USA. Preparation of aryl substituted cyclopropylcarboxamides for therapeutic use as glucokinase activators. WO2004063179; 2004
   Google Scholar
• F. Hoffmann-La Roche AG, Switz. Process for preparation of piragliatin. WO2007115968; 2007
   Google Scholar
• OSI Pharmaceuticals, Inc., USA; Prosidion Ltd; OSI Pharm Inc. Preparation of tri(cyclo) substituted amides, in particular N-(thiazol-2-yl) amides, as Glucokinase (GK) activators for treating hyperglycemia and diabetes. WO2004072031; 2004
   Google Scholar
• Bristol-Myers Squibb Company, USA. Preparation of novel thiazolyl benzeneacetamide derivatives as glucokinase activators. WO200805914; 2008
   Google Scholar
• F. Hoffmann-La Roche AG. Glucokinase activators. WO20000058293; 2000
   Google Scholar
• Grimsby J, Sarabu R, Corbett WL, et al. Allosteric activators of glucokinase: Potential role in diabetes therapy. Science 2002;201:270-2
   Google Scholar
• Grimsby J, Matschinsky FM, Grippo JG. Discovery and actions of glucokinase activators. In: Matschinsky FM, Magnuson MA, editors, Glucokinase and glycemic disease – From basics to therapeutics; 2003. p. 260-78
   Google Scholar
• Sarabu R, Grimsby J. Targeting glucokinase activation for the treatment of type 2 diabetes – a status review. Curr Opin Drug Discov Dev 2005;8:631-7
   PubMed Web of Science ®Google Scholar
• Kietzmann T, Ganjam G. Glucokinase: old enzyme, new target. Expert Opin Ther Patents 2005;15:705-13
   Web of Science ®Google Scholar
• Efanov AM, Barrett DG, Brenner BM, et al. A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology 2005;136:2696-701
   Google Scholar
• Fyfe MCT, White JR, Taylor A, et al. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions. Diabetologia 2007;50:1277-87
   PubMed Web of Science ®Google Scholar
• AstraZeneca AB, Swed.; AstraZeneca UK Limited. Preparation of benzamides affecting glucokinase for combined treatment or prevention of type 2 diabetes and obesity. WO2003015774; 2003
   Google Scholar
• Pfizer Products Inc., USA. Preparation of fused phenyl amido heterocycles for the prevention and treatment of glucokinase-mediated diseases. WO2007122482; 2007
   Google Scholar
• Takeda Pharmaceutical Company Limited, Japan; Takeda San Diego, Inc. Preparation of imidazopyridine compounds as glucokinase activators for treating diabetes, obesity, and similar disorders. WO2007028135; 2007
   Google Scholar
• AstraZeneca AB, Swed.; AstraZeneca UK Limited. Preparation of imidazopyridines, imidazopyrazines, and purines as glucokinase activators for treatment of type 2 diabetes. WO2006125958; 2006
   Google Scholar
• Hoffmann-La Roche Inc., USA. Preparation of N-heterocyclylindole-3-carboxamides as glucokinase activators. US20040067939; 2004
   Google Scholar
• Takeda Pharmaceutical Company Limited, Japan. Preparation of indoles and related compounds as glucokinase activators. WO2006112549; 2006
   Google Scholar
• AstraZeneca AB, Swed.; AstraZeneca UK Limited. Preparation of benzofuran derivatives for treatment of glucokinase-mediated disease. WO2004046139; 2004
   Google Scholar
• Banyu Pharmaceutical Co., Ltd., Japan. Preparation of 2-heteroaryl-substituted benzimidazole derivatives as glucokinase activators. WO2005063738; 2005
   Google Scholar
• Novo Nordisk A/S, Den. Preparation of N-heteroaryl indole carboxamides and analogs thereof, for use as glucokinase activators in the treatment of diabetes. WO2005049019; 2005
   Google Scholar
• Takeda Pharmaceutical Company Limited, Japan; Takeda San Diego, Inc. WO2007075847; 2007
   Google Scholar
• Astellas Pharma Inc., Japan. Preparation of heterocyclic compounds as glucokinase activators for the treatment of diabetes. WO2007043638; 2007
   Google Scholar
• AstraZeneca AB, Swed.; AstraZeneca UK Limited. Preparation of quinoline derivatives as glucokinase inhibitors. WO2004045614; 2004
   Google Scholar
• Banyu Pharmaceutical Co., Ltd, Japan. Preparation of substituted quinazoline and pyridopyrimidine derivatives as glucokinase activators. WO2005090332; 2005
   Google Scholar
• Banyu Pharmaceutical Co., Ltd., Japan. Preparation of aminobenzamide derivatives for treatment of diabetes and obesity. WO2003080585; 2003
   Google Scholar
• Kamata K, Mitsuya M, Nishimura T, et al. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 2004;12:429-38
   PubMed Web of Science ®Google Scholar
• Futamura M, Hosaka H, Kadotani A, et al. An allosteric activator of glucokinase impairs interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. J Biol Chem 2006;281:37668-74
   PubMed Web of Science ®Google Scholar
• Novo Nordisk A/S, Den.; Valcarce-Lopez, Mariacarmen, et al. Preparation of thiazolyl aryl ureas as activators of glucokinase. WO2004002481; 2004
   Google Scholar
• Array Biopharma Inc., USA. Preparation of pyridine derivatives and analogs thereof as glucokinase activators. WO2007053345; 2007
   Google Scholar
• Banyu Pharmaceutical Co., Ltd., Japan. Preparation of pyridinecarboxamide derivatives having glucokinase activating effect for the treatment of diabetes. WO2004081001; 2004
   Google Scholar
• Brocklehurst KJ, Payne VA, Davies RA, et al. Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. Diabetes 2004;53:535-41
   PubMed Web of Science ®Google Scholar
• McKerrecher D, Allen JV, Caulkett PWR, et al. Design of a potent, soluble glucokinase activator with excellent in vivo efficacy. Bioorg Med Chem Lett 2006;16:2705-9
   PubMed Web of Science ®Google Scholar
• Coope GJ, Atkinson AM, Allot C, et al. Predictive blood glucose lowering efficacy by glucokinase activators in high fat fed female Zucker rats. Br J Pharmacol 2006:1-8
   Google Scholar
• Johnson D, Shepherd RM, Gill D, et al. Glucose-dependent modulation of insulin secretion and intracellular calcium ions by GKA50 – A glucokinase activator. Diabetes 2007;56:1694-702
   PubMed Web of Science ®Google Scholar
• F. Hoffmann-La Roche A-G, Switz. Isoindolin-1-one glucokinase activators, and their pharmaceutical compOSItions, preparation, and use in the treatment or prophylaxis of type II diabetes. WO2002048106; 2002
   Google Scholar
• F. Hoffmann-La Roche A-G, Switz. Preparation of dioxoimidazolidinylalkylcarboxamides as glucokinase activators for treatment of type II diabetes. WO2001083478; 2001
   Google Scholar
• Takeda San Diego, Inc., USA. Preparation of 1-pyrimidinyl or 3-quinazolinyl alkanamides as glucokinase activators. WO2007104034; 2007
   Google Scholar
• Takeda San Diego, Inc., USA. Preparation fused pyrazole and pyrrolidine derivatives as glucokinase activators. US2007281942; 2007
   Google Scholar
• Janssen Pharmaceutica NV, Belg. Substituted hexahydroisoindolones and cyclopentapyrrolones as allosteric modulators of glucokinase, their preparation, pharmaceutical compOSItions, and use in therapy. WO2007053765; 2007
   Google Scholar
• Janssen Pharmaceutica NV, Belg. Substituted pyrrolones as allosteric modulators of glucokinase, their preparation, pharmaceutical compositions, and use in therapy. US2007099937; 2007
   Google Scholar
• Takeda Pharmaceutical Company Limited, Japan; Takeda San Diego, Inc. Preparation of indazolamines as glucokinase activators. WO2007075847; 2007
   Google Scholar
• Takeda San Diego, Inc., USA. Pyrazole and triazole derivatives as glucokinase activators and their preparation, pharmaceutical compOSItions and use in the treatment of diseases. WO2007061923; 2007
   Google Scholar
• Dunten P, Swain A, Kammlott U. Crystal structure of human liver glucokinase bound to small molecule allosteric activator: Insights into activating mutations. In: Matschinsky FM, Magnuson MA, editors, Glucokinase and glycemic disease – From basics to therapeutics; 2004. p. 145-54
   Google Scholar
• Available from: http://www.roche.com/home/investors/inv_pipeline/inv_pipeline_det.htm?ta=%25&Phase=%25&submit=Show+pipeline
   Google Scholar